Doctor profile · Federal record
Dr. Rachel Smith, P.A.
Physician Assistant · Longview, TX
- NPI 1851323919
- Accepts Medicare
- MIPS 88.5 / 100 · 2023
- 23 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
3535 N Fourth St Ste 400
Longview, TX 756050038
(903) 757-3881
fax (903) 757-5948
Credentials & registration
- NPI registered
- July 2006 — 20 yrs on file
- Profile last updated
- August 30, 2022
- Year of graduation
- 2003 — 23 yrs since
- Specialty taxonomy
- 363A00000X — NUCC code
- State license (1)
- Texas #PA03793
- Medicaid
- TX #302339201
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1851323919. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
4,855
Distinct HCPCS
10
Medicare allowed
$214,571
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 2,255 | 352 | $5 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 621 | 540 | $74 | |
17000 |
Destruction of precancer skin growth, 1 growth | 560 | 441 | $42 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 382 | 323 | $105 | |
17110 |
Destruction of skin growth, 1-14 growths | 282 | 245 | $87 | |
11102 |
Biopsy of related skin growth, first growth | 205 | 182 | $72 | |
99204 |
New patient office or other outpatient visit, 45-59 minutes | 156 | 156 | $136 | |
17004 |
Destruction of precancer skin growth, 15 or more growths | 66 | 55 | $139 | |
J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 46 | 11 | $1 | |
11301 |
Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 39 | 37 | $95 |
In context: peer comparison
Among 16 peers in this city , average services per provider: 153. This provider delivers 32× the peer median.Open Payments
Industry payments received
All-time total
$1,901
Transactions
91
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| ABBVIE INC. | 29 | $403.87 | |
| Lilly USA, LLC | 11 | $175.48 | |
| Medtronic, Inc. | 3 | $148.01 | |
| GENZYME CORPORATION | 6 | $135.26 | |
| Regeneron Healthcare Solutions, Inc. | 4 | $125.09 | |
| Novartis Pharmaceuticals Corporation | 6 | $105.78 | |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 4 | $100.37 | |
| Galderma Laboratories, L.P. | 5 | $94.87 | |
| E.R. Squibb & Sons, L.L.C. | 6 | $91.92 | |
| LEO Pharma Inc. | 3 | $83.74 | |
| Incyte Corporation | 4 | $83.57 | |
| STRATA Skin Sciences, Inc. | 1 | $81.59 | |
| Janssen Biotech, Inc. | 2 | $67.24 | |
| UCB, Inc. | 3 | $63.40 | |
| PFIZER INC. | 4 | $55.60 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
591
Patients
332
Total drug cost
$112,727
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Minocycline Hcl | Generic | 85 | 28 | $2,314 |
| Mometasone Furoate | Generic | 75 | 49 | $1,996 |
| Ketoconazole | Generic | 73 | 48 | $1,820 |
| Triamcinolone Acetonide | Generic | 59 | 45 | $921 |
| Methotrexate (Methotrexate Sodium) | Brand | 53 | 13 | $1,788 |
| Clobetasol Propionate | Generic | 47 | 33 | $3,841 |
| Betamethasone Dipropionate | Generic | 40 | 28 | $2,056 |
| Hydrocortisone | Generic | 37 | 30 | $230 |
| Hydroxychloroquine Sulfate | Generic | 20 | 0 | $501 |
| Terbinafine Hcl | Generic | 20 | 14 | $317 |
Frequently asked questions
What is Dr. Rachel Smith's medical specialty?
Dr. Rachel Smith practices Physician Assistant in Longview, TX.
Where does Dr. Rachel Smith practice?
Dr. Rachel Smith practices at 3535 N Fourth St Ste 400, Longview, TX 756050038. Office phone: 9037573881.
What is Dr. Rachel Smith's NPI?
Dr. Rachel Smith's National Provider Identifier (NPI) is 1851323919, issued by NPPES.
Does Dr. Rachel Smith accept Medicare assignment?
Yes. Dr. Rachel Smith accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Rachel Smith commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Established patient office or other outpatient visit (HCPCS 99213); Destruction of precancer skin growth, 1 growth (HCPCS 17000). Source: CMS Medicare Physician & Other Practitioners file.